In the last trading session, 1.15 million shares of the Tango Therapeutics Inc (NASDAQ:TNGX) were traded, and its beta was 0.89. Most recently the company’s share price was $1.84, and it changed around -$0.06 or -3.16% from the last close, which brings the market valuation of the company to $198.91M. TNGX currently trades at a discount to its 52-week high of $12.02, offering almost -553.26% off that amount. The share price’s 52-week low was $1.81, which indicates that the current value has risen by an impressive 1.63% since then.
Tango Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.12. If we narrow it down even further, the data shows that 0 out of 9 analysts rate the stock as a Sell; another 3 rate it as Overweight. Among the rest, 0 recommended TNGX as a Hold, whereas 6 deemed it a Buy, and 0 rated it as Underweight. Tango Therapeutics Inc is expected to report earnings per share of -0.35 for the current quarter.
Tango Therapeutics Inc (NASDAQ:TNGX) trade information
Instantly TNGX has showed a red trend with a performance of -3.16% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 2.4400 on recent trading dayincreased the stock’s daily price by 24.59%. The company’s shares are currently down -40.45% year-to-date, but still down -20.00% over the last five days. On the other hand, Tango Therapeutics Inc (NASDAQ:TNGX) is -38.26% down in the 30-day period.
The consensus price target as assigned by Wall Street analysts is $18, which translates to bulls needing to increase their stock price by 89.78% from its current value. Analyst projections state that TNGX is forecast to be at a low of $18 and a high of $18.
Tango Therapeutics Inc (TNGX) estimates and forecasts
The year-over-year growth rate is expected to be -30.63%, down from the previous year.
Consensus estimates provided by 7 financial analysts predict the company will bring in an average of 6.8M in revenue for the current quarter. 7 analysts expect Tango Therapeutics Inc to make 6.49M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 6.47M and 19.88M respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 5.10%. Forecasts for the next quarter put sales growth at -67.36%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 7.47%. Tango Therapeutics Inc earnings are expected to increase by -12.98% in 2025, but the outlook is negative -10.49% per year for the next five years.
TNGX Dividends
Tango Therapeutics Inc’s next quarterly earnings report is expected to be released in April.
ECOR1 CAPITAL, LLC, with 12.3075% or 13.33 million shares worth $114.38 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
Vanguard Total Stock Market Index Fund and Price (T.Rowe) Small-Cap Value Fund were the top two Mutual Funds as of Sep 30, 2024 . The former held 2.03 shares worth $3.73 million, making up 1.88% of all outstanding shares. On the other hand, Price (T.Rowe) Small-Cap Value Fund held roughly 1.66 shares worth around $3.06 million, which represents about 1.54% of the total shares outstanding.
